Who are ZYN002 - transdermal gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cannabis Sativa Oil, Hemp, Cannabis oil, dl-Methylphenidate plus Cannabidiol, MediCabilis CBD Oil, Cannabis Extract Oil SR Capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zyn002-transdermal-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ZYN002 - transdermal gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ZYN002 - transdermal gel (ZYN002 - transdermal gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cannabinoid. Area: Epilepsy.

phase 3 cannabinoid CB2 receptor Epilepsy Small molecule Live · refreshed every 30 min

Target snapshot

ZYN002 - transdermal gel (ZYN002 - transdermal gel) — Zynerba Pharmaceuticals, Inc.. ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ZYN002 - transdermal gel TARGET	ZYN002 - transdermal gel	Zynerba Pharmaceuticals, Inc.	phase 3	cannabinoid	CB2 receptor
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor
Cannabis oil	Cannabis oil	Assaf-Harofeh Medical Center	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cannabinoid class)

Aphios · 1 drug in this class
Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 drug in this class
Scilex Pharmaceuticals, Inc. · 1 drug in this class
Wolfson Medical Center · 1 drug in this class
Zynerba Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZYN002 - transdermal gel — Competitive Intelligence Brief. https://druglandscape.com/ci/zyn002-transdermal-gel. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab